ATXS
Income statement / Annual
Last year (2024), Astria Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Astria Therapeutics, Inc.'s net income was -$94.26 M.
See Astria Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$500.00 K |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$26.00 K
|
$119.00 K
|
$0.00
|
$395.00 K
|
$202.00 K
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$26.00 K
|
-$119.00 K
|
$500.00 K
|
-$395.00 K
|
-$202.00 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
| Research and Development Expenses |
$77.11 M
|
$57.33 M
|
$34.26 M
|
$15.55 M
|
$25.59 M
|
$18.32 M
|
$17.04 M
|
$18.68 M
|
$25.45 M
|
$23.03 M
|
| General & Administrative Expenses |
$34.45 M
|
$25.70 M
|
$19.24 M
|
$14.81 M
|
$11.85 M
|
$8.77 M
|
$9.33 M
|
$8.91 M
|
$10.11 M
|
$8.63 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$34.45 M
|
$25.70 M
|
$19.24 M
|
$14.81 M
|
$11.85 M
|
$8.77 M
|
$9.33 M
|
$8.91 M
|
$10.11 M
|
$8.63 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$176.00 K
|
$32.00 K
|
$93.00 K
|
$7.00 K
|
| Operating Expenses |
$111.56 M
|
$83.03 M
|
$53.50 M
|
$30.36 M
|
$37.44 M
|
$27.09 M
|
$26.37 M
|
$27.59 M
|
$35.56 M
|
$31.66 M
|
| Cost And Expenses |
-$111.56 M
|
$83.03 M
|
$53.50 M
|
$30.36 M
|
$37.44 M
|
$27.09 M
|
$26.37 M
|
$27.59 M
|
$35.56 M
|
$31.66 M
|
| Interest Income |
$17.36 M
|
$10.20 M
|
$1.72 M
|
$122.00 K
|
$236.00 K
|
$845.00 K
|
$425.00 K
|
$160.00 K
|
$242.00 K
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$100.00 K
|
$462.00 K
|
$837.00 K
|
$978.00 K
|
| Depreciation & Amortization |
$0.00
|
-$15.20 M
|
$228.49 K
|
-$164.62 M
|
$26.00 K
|
$26.00 K
|
$119.00 K
|
$304.00 K
|
$395.00 K
|
$202.00 K
|
| EBITDA |
-$94.26 M |
-$83.03 M |
-$53.50 M |
-$194.98 M |
-$37.44 M |
-$26.27 M |
-$25.65 M |
-$26.60 M |
-$34.83 M |
-$31.46 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-53.2
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-54.19
|
0
|
0
|
| Total Other Income/Expenses Net |
$17.30 M
|
$10.14 M
|
$1.67 M
|
$64.00 K
|
$135.00 K
|
$795.00 K
|
$501.00 K
|
-$270.00 K
|
-$502.00 K
|
-$971.00 K
|
| Income Before Tax |
-$94.26 M
|
-$72.89 M
|
-$51.83 M
|
-$194.91 M
|
-$37.30 M
|
-$26.29 M
|
-$25.87 M
|
-$27.36 M
|
-$36.06 M
|
-$32.63 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-54.73
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
-$164.74 M
|
$0.00
|
-$50.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$94.26 M
|
-$72.89 M
|
-$51.83 M
|
-$194.91 M
|
-$37.30 M
|
-$26.24 M
|
-$25.87 M
|
-$27.36 M
|
-$36.06 M
|
-$32.63 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-54.73
|
0
|
0
|
| EPS |
-1.68 |
-2.42 |
-3.55 |
-24.58 |
-12.2 |
-14.06 |
-30.71 |
-75.73 |
-133.31 |
-243.45 |
| EPS Diluted |
-1.68 |
-2.42 |
-3.55 |
-24.58 |
-12.2 |
-14.06 |
-30.71 |
-75.73 |
-133.31 |
-243.45 |
| Weighted Average Shares Out |
$56.16 M
|
$30.12 M
|
$14.62 M
|
$8.93 M
|
$3.06 M
|
$1.87 M
|
$842.47 K
|
$361.36 K
|
$270.50 K
|
$134.03 K
|
| Weighted Average Shares Out Diluted |
$56.16 M
|
$30.12 M
|
$14.62 M
|
$8.93 M
|
$3.06 M
|
$1.87 M
|
$842.47 K
|
$361.36 K
|
$270.50 K
|
$134.03 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
